Enzyme replacement therapy interruption in patients with Mucopolysaccharidoses: Recommendations for distinct scenarios in Latin America
Background: Mucopolysaccharidoses (MPS) are a group of lysosomal storage disorders, leading to the progressive accumulation of glycosaminoglycans (GAGs) and the subsequent compromising of tissues and organ malfunction. Although incurable, most types of MPS can be treated with enzyme replacement ther...
Main Authors: | Martha L. Solano, Alejandro Fainboim, Juan Politei, Gloria L. Porras-Hurtado, Ana Maria Martins, Carolina F. Moura Souza, Felipe Mendez Koch, Hernan Amartino, Jose Maria Satizábal, Dafne D.G. Horovitz, Paula F.V. Medeiros, Rachel S. Honjo, Charles M. Lourenço |
---|---|
Format: | Article |
Language: | English |
Published: |
Elsevier
2020-06-01
|
Series: | Molecular Genetics and Metabolism Reports |
Subjects: | |
Online Access: | http://www.sciencedirect.com/science/article/pii/S2214426920300185 |
Similar Items
-
Intravenous Enzyme Replacement Therapy in Mucopolysaccharidoses: Clinical Effectiveness and Limitations
by: Rossella Parini, et al.
Published: (2020-04-01) -
Interruption science as a research field: Towards a taxonomy of interruptions as a foundation for the field
by: Fabian J. Stangl, et al.
Published: (2023-03-01) -
Current and new therapies for mucopolysaccharidoses
by: Monica Penon-Portmann, et al.
Published: (2023-02-01) -
The exit failure in interrupted cutting/
by: Pekelharing, A. J., et al. -
Human Interruption Management in Workplace Environments: An Overview
by: M. Alkahtani, et al.
Published: (2020-04-01)